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Summary: This first report describes a variant form of lipase in the serum of a woman suffering from a
malignant non-Hodgkin lymphoma. Activity measurements of serum lipase and amylase showed persistently
elevated activities of lipase with simultaneously normal activities of amylase. Results of exclusion chromatog-
raphy and immunological investigations clearly demonstrate that the atypical time-course of lipase activity is
not due to injury of the pancreas or alterations of the patient's lipase, but rather due to the presence of lipase-
binding autoantibodies, resulting in the formation of immune complexes with high molecular mass
( > 200000) between lipase and immunoglobulin G lambda. A clinical significance, if any, of this macro
lipase has yet to be determined.
Introduction
Determination of the activity of lipase (triacylglycer-
olacyljiydrolase, EC 3.1-1-3) is commonly perfofmed'
in sera of patients with possible pancreatitis, and it is
also used to advantage to document the course of
acute and recurrent pancreatitis (l, 2). National and
international recommendations for the standardisa-
tion of the analytical and the diagnostic procedures
for this enzyme are still lacking. We, äs well äs others,
therefore usually determine lipase and amylase (1,4-
-jD-glucan glucanohydrolase, EC 3.2.1.1) activities
in parallel in order to combine the technical reliability
of the recently developed methods for total activity
of amylase (3 — 8) with the organ specificity of a lipase
determination (9 —14).
In the serum of a female patient suffering from a non-
Hodgkin lymphoma we observed significantly elevated
lipase activities (up to 7 times the upper reference
limit) for several weeks. Usually the finding of such
an increased serum lipase activity is regarded äs a
specific indicator of acute injury to the pancreas.
However, in this case the reason for the elevated lipase
activities was unclear, because total amylase activities
always remained normal. Several possible mecha-
nisms can explain such unusual enzyme patterns:
1. Inhibition of amylase activity or release.
2. Occurrence of an unusual lipase isoenzyme.
3. Decrease of the rate of elimination of lipase activ-
ity.
4. Persistence of lipase in blood after complexation
of lipase with a plasma protein and formation of
macro lipase.
Here we report a case of macro lipase, which, to our
knowledge is the first description of serum lipase
linked to immunoglobulin G lambda.
Materials and Methods
Samples
Serum specimens were either analysed on the same day they
were obtained, stored at 4 °C for not longer than 24 h, or were
kept at —20 °C without any additives until the assay.
Enzyme assays
We measured lipase catalytic activity with a turbidimetric
method (cat. Nos. 159697 and 262358, Boehringer Mannheim,
Mannheim, F. R. G.) and the recently introduced lipase-UV
method (code No. 999-00508, Wako Chemicals GmbH, Neuß,
F. R. G.) at 25 °C and 37 °C according to the manufacturers'
instructions. The activities were determined using either a spec-
trometer (Model M 1101) or an ACP 5040 Instrument (both
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from Eppendorf Ger tebau, Hamburg, F. R. G.)· We also per-
formed mass determinations of lipase with an immunoassay
(Enzygnost-Lipase, cat. No. OUEK 10/11, lot. No. 17862,
Behringwerke, Marburg, F. R. G.) according to the manufac-
turer's instructions. Amylase activity was determined at 25 °C
using Testomar-Amylase (cat. No. 0SW 10, Behringwerke).
Determinations of other serum enzyme activities were per-
formed according to the recommendations of the Deutsche
Gesellschaft f r Klinische Chemie (15). Differentiation of serum
immunoglobulins was obtained using the Paragon IFE System
(Beckman Instruments GmbH, M nchen, F. R. G.).
Exclusion chromatography
A 26 χ 0.9 cm column packed with Sephacryl S-300 sf (Phar-
macia, Uppsala, Schweden) was used with a mobile phase
containing, per liter, 50 mmol of Tris (pH 7.0), 50 mmol of
NaCl, and 200 mg of NaN3. The sample volume was 200 μΐ,
the flow rate about 3 ml/h, and the fraction volume 440 μΐ.
Post-column lipase activities and concentrations were deter-
mined using the enzyme assays described. To increase sensitivity,
the sample volume was doubled and the activity was measured
at 37 °C.
For determination of the relative molecular masses the column
was calibrated s described previously (16); it was also cali-
brated with a serum containing IgG-linked creatine kinase-BB,
of which the molecular mass had been determined by gradient
electrophoresis On polyacrylamide gel (16).
Aff in i ty chromatography
500 μΐ of serum containing IgG-linked lipase was adsorbed on
a column (3 χ 0.4 cm) packed with Protein A-Sepharose CL-
4B (Pharmacia) (17). Normal-sized lipase and other serum
constituents not bound to the column matrix were eluted with
ten 0.5 ml fractions of Tris buffer (50 mmol/1, pH 8.0) contain-
ing, per liter, 50 mmol of NaCl and 200 mg of NaN3. The IgG-
bound lipase was detached from Protein A with ten 0.5 ml
fractions of 0.5 mol/1 acetic acid (pH 3). The fractions eluted
from the column were neutralized with 500 μΐ of Tris buffer
and lipase determined s described above.
Purification of IgG
After heat inactivation of lipase activity (2.5 h, 50 °C), immu-
noglobulin G (subclasses l, 2, 4) was purified from 4 ml serum
by affinity chromatography on Protein A-Sepharose CL-4B s
described earlier (18). Proteins not retained by the column were
collected, neutralized and concentrated in the same way (solu-
tion A).
of lipase activity in the supernatants the tubes were incubated
overnight at 4 °C. To increase sensitivity and precision, the
sample volume was increased s indicated.
Investigation of catalytic activity
To assess the therm stability of lipase in the samptes we deter-
mined heat inactivation at 50 °C and at three dififerent pH
values (6.5, 7.4, 8.3). Possible inhibiti ii of the activity of lipase
by the lipase-binding antibodies was determined by titration of
human Hpase with the IgG preparation of seruin Lut. To 100
μΐ of a serum with elevated normal-sized lipase (catalytic con-
centration ca. 700 U/l at 25 °C) we added increasing amounts
of lipase-binding IgG and supplememted the mixture with so-
lution A to give a final volume of 200 μΐ in each tube. The
tubes were incubated for 36 h at 4 °C, followed by determina-
tion of lipase activity. Apparent energies of activation of the
lipase-catalysed reaction were determined s described previ-
ously (19) for creatine kinase isoenzymes and macro creatine
kinase.
Case Report
The sera studied were obtained from patient Lut., a wpman
aged 45 years with a non-Hodgkin lymphoma classiiled s low
malignant. During her stay, therapy was initiated according to
the ALL protocpl (cf. legend to flg. 1). During this therapy,
growth of the tumour was progredient which e. g. could be
documented by increasing amounts of y^globulins (fraction
0.25, total pr tein 63 g/l) and the proof of bands of apparently
monoclonal origin. Additionally she developed increasing ac-
tivities of serum lipase without any clinical signs or complaints
and without characteristic radiographic and ultrasonographic
findings suspicious of pancreatitis or other affections of this
organ (fig. 1), and without a concomitant elevation of her serum
amylase activity. As this type of therapy proved to be unsuc-
cessful, another scheme (VIM/BLEO) (cf. legend to fig. 1) was
chosen which was more successful, and in the course of which
lipase activity and relative amount of immunoglobulins nor-
malized (γ-globulin fraction 0.19, total pr tein 62 g/l).
The results presented in our paper were obtained from experi-
ments with samples taken at November 6, 10, and 12 (fig. 1),
when macro lipase activity was highest.
Results
The persistently raised activity of lipase without con-
comitant increase of amylase activity was investigated
and is explained by the pfesence of a macro lipase.
Recombination of macro lipase in vitro
The purified IgG solution was either incubated with a serum
of a patient with acute pancreatitis or with lipase prepared from
human pancreas fluid for l h at 4 °C before exclusion chro-
matography.
Immunological techniques
The serum containing macro lipase and controls were reacted
with specific antisera against human immunoglobulins. These
included anti-IgA, anti-IgM, anti-IgG (all from Dako,
K0benhavn, Denmark), anti-kappa and anti-lambda (Behring-
werke). To constant amounts of lipase activity (25 μΐ) we added
increasing volumes of the respective antisera, imidazole buffer
(100 mmol/1, pH 6.9 at 25 °C) and polyethylene glycol 6000
solution to give a final volume of 200 μΐ. The final concentratipn
of polyethylene glycol 6000 was 30 g/l. Before determination
Molecular size
Figure 2 shows the typical patterns obtained by size
exclusion chromatography on the Sephacryl S-300 sf
column. In contrast to normal-sized lipase present in
the serum of a patient suffering of acute pancreatitis,
which elutes with maximum activity in fraction 33,
under the same conditions the lipase activity of serum
Lut. is eluted earlier with maximum activity in frac-
tions 26/27. This distinctly higher relative molecular
mass of about 250 000 is due to complexation of the
lipase with IgG s shown below. The incre se of the
relative molecular mass is not due to complexation
with colipase (results not shownX
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Fig. l. Time-course of enzyme activities.
ALL protocol: therapy with vincristine, daunorubicine, asparaginase, prednisolone.
VIM/BLEO scheme: therapy with etoposide, methotrexate, ifosfamide, bleomycine.
o—o: lipase activity, x—x:amylase activity, o —o: lactate dehydrogenase activity, Δ — Δ : γ-glutamyltransferase activity,
H h: alanine aminotransferase activity.
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Fig. 2. Exclusion-chromatographic pattern of serum lipases.
Conditions of tun: see text.
o—o: serum of patient Lut. (macro lipase).
x—x: serum of a patient with pancreatitis (npnnal-sized
lipase).
o—0: mixture of equal amounts of both sera.
Evidence of lipase-binding immunoglobulins
Macro lipase was separated frpm the serum by affmity
chromatography on Protein A^Sepharose CL-4B. As
already described (17, 18, 20), not only free immu-
noglobulin G but also enzyme-linked immunoglobulin
G is quantitatively fixed by Protein A (fig. 3), whereas
normal-sized lipase passes the cpl mn without reten-
tion. Binding occurs via the Fc fragment of the im-
munoglobulins, leaving the antigen-binding sites un-
affected. The bound maero lipase afterwkrds was de-
tached by decreasing the pH of the mobile phase to
about 3.0.
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Fig. 3. A inity chromatography on Protein A-Sepharose CL-
4B. Conditions of run: see text; fraction of 500 μΐ were
collected.
x...x: normal-sized lipase.
o —o: IgG-linked lipase.
Lipase-free immunogtobulins of serum Lut. prepared
after heat inactivation by affinity chromatography,
recombined not only with autologous but also with
homologous lipase to form macro lipase. Both meth-
ods gave the same Information when used for the
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analysis of the lipase activity of chromatography frac-
tions (fig. 4). It was therefore possible to document
the re-formation of macro lipase and to exclude pos-
sible artifacts. Correlation between both activity de-
terminations (Bö = Boehringer, Wa = Wako) was:
y(Bö) = 1.76 x(Wa) - 8.7, r = 0.98, N = 20.
The binding immunoglobulins are present in the
serum in excess of the lipase. Figure 2 documents the
results obtained after mixing equal amounts of serum
Lut. with a serum of a patient with pancreatitis (lipase
catalytic concentration about 1000 U/l at 25 °C). The
normal-sized lipase is quantitatively converted into
macro lipase and elutes with maximum activity in
fractions 26/27 after exclusion chromatography.
For amylase activity we obtained the results expected
(not shown), and did not detect any significant Inhi-
bition.
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Fig. 4. Complexation of lipase by speciflc immunoglobulins.
Exclusion-chromatographic pattern.
Conditions of run: see text.
Incubation of nonnal-sized pancreas lipase (o) with IgG
prepared from serum Lut. resulted in re-fonnation of
macro lipase (o). Lipase activities were determined by
the turbidimetric method (Boehringer) (—), by the UV
assay (Wako) (···), and by the immunological procedure
(Behringwerke) (—).
Immunological investigations
Reacting the serum with antisera directed against the
G class of heavy and the lambda class of light chains
of human immunoglobulins precipitated significant
amounts of enzyme activity in the quantitative pre-
cipitation test. Partial preeipitation was achieved by
anti-kappa antibodies (fig. 5). Thbre was no decfease
in lipase activity in the supernatant when the serum
IgM ör IgA were piecipitated with specific antisera.
350-1
300J
200-1
150-
100-
50-
30J
50 100
Antiserum [ ]
150
Fig. 5. Precipitation test.
y-axis: residual lipase activity of the supernatants after
precipitation of the respective immunoglobulins.
Upper panel: serum of a patient with aeute pancreatitis.
Lower panel: serum Lut.
Types of antisera added: o: anti-IgG, p: anti-IgA,
x: anti-IgM, : anti-kappa, V: anti-lambdä.
The commercially available antibodies directed
against lipase detected the lipase nioiety of the macro
lipase not only in the serum samples but also in the
chromatography fraetions (fig. 4).
Investigations concerning catalytic activity
Specific activity (U/mg) at 25 °C was calculated by
dividing the results of the activity measurements (U/l)
by the results of the immunoassay (mg/1). We could
not substantiate charaetefistic diffefences between
normal lipase (2400 U/mg) and macro lipase (2500
U/ing), regärdless of whether we assayed whole seruni
or the chromatography fractions.of figure 4.
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Titration of normal-sized lipase with lipase-binding
immunoglobulin G prepared from serum Lut., re-
sulted in an Inhibition of enzyme activity. The increas-
ing amounts of the autoantibody converted normal-
sized lipase into the macro form and simultaneously
inhibited enzyme activity by about 30%.
Furthermore we determined the decrease in enzyme
activity of macro lipase caused by thermal inactiva-
tion and shifts in pH during storage at 50 °C. There
was no difference between normal-sized and Ig-linked
lipase; generally inactivation increased with increasing
pH values of the matrix (results not shown).
Dependence of enzyme activity on temperature was
determined with both tests. At higher temperatures
the Arrhenius plots deviate from a linear relationship
(fig. 6). We therefore only calculated apparent energies
of activation for the temperature interval 25 — 34 °C.
The activation energies compare well with recently
published results (22), which were obtained using dif-
ferent assays. Determinations of the energies of acti-
vation by the assays used in our study (tab. 1) do not
allow differentiation of the two types of lipase.
6.2i
6.0
5.8
5.0
4.8
4.6
4.4-
37 34 30
Temperature [°C]
25
3.20 3.25 3.30
Temperature [103K-1]
3.35
Tab. 1. Activation energies (kJ/mol). Average, apparent values
determined for a temperature interval from 25 to 34 °C.
Method of activity
determination
Macro
lipase
Normal-size
lipase
Turbidimetric assay
(Boehringer)
UV assay
(Wako)
23
26
20
21
Fig. 6. Enzyme activity äs a function of temperature. Catalytic
concentration b [U/l] plotted äs natural logarithm.
Upper panel: activity determined by the turbidimetric
assay (Boehringer). ·
Lower panel: activity determined by the UV assay
(Wako).
o—·: macro lipase, o—o: normal-sized lipase.
Discussion
Our documentation of lipase-IgG complexes (macro
lipase) in the serum of a patient suffering from a
malignant lymphoma is based on the following re-
sults:
1. During exclusion chromatography the vast major-
ity of the patient's lipase eluted a little later than IgG-
linked creatine kinase-BB under the same conditions,
its elution volume corresponding to a relative molec-
ular mass of about 250 000. Such relative molecular
masses are expected for complexes with a 2: l molar
ratio between lipase and IgG, but not for uncom-
plexed lipase (molecular mass 48 000) (for references
see 1. c. (1)). Complexes of the same 2 : l molar ratio
have recently been reported for IgG(kappa)-linked
creatine kinase-BB, IgG(lambda)-linked creatine ki-
nase-BB (18) and IgA(kappa)-linked lactate dehydro-
genase isoenzyme 5 (23).
2. The nature of the immunoglobulins binding to
lipase was elucidated by immunological methods: the
heavy chains belong to the gamma, the light chains
to the lambda class.
3. The Fc regions of the binding IgG are free, because
the macromolecular complexes are quantitatively
fixed by Protein A. This in turn suggests that lipase
is attached to the Fab regions of IgG and that the
complexes are immune complexes formed by an an-
tibody^antigen reaction.
4. The binding is reversible: thermal inactivation de-
stroyed all serum lipase activity. After purification
and preparation of the IgG it easily combined with
exogenous lipase to form macro lipase again. This
observation furthermore indicates that the patient's
lipase is apparently not modified in a way that would
cause complex formation. Binding of lipase to the
IgG is accompanied by a slight, probably steric, in-
hibition of catalytie activity. There was no evidence
for changes in thermal stability, in stability to shifts
of pH, in catalytie efficiency expressed äs activation
energy, or in specific activity, which was recently
reported to ränge from 1000-3000 U/mg (25 °C) in
human serum (24). It is not known whether this wide
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ränge is due to intra-individual variations, due to
analytical imprecisions or both. The Inhibition of
lipase activity after complexing with IgG apparently
is accompanied by a concomitant alteration of the
mass determination applied, because we could not
substantiate differences in the specific activities
(U/mg) of lipase and macro lipase.
5. The antibodies are present in the patient's serum
in excess of the endogenous lipase, therefore it is very
unlikely that macro lipase is a result of a variant gene.
Our results indicate that a specific antigen-antibody
reaction is responsible for this postsynthetic modifi-
cation of lipase and for the observed existence of
macro lipase, and that macro lipase therefore may be
regarded äs a new niember of the family of the Ig-
linked enzymes (25 — 33) of which the first, macro
amylase, was described in 1964.
The presence of macro lipase in this serum may be
explained by the production of a specific immuno^
globulin G with high affinity for lipase. This points
to associationsNbetween autoimmune phenomena, ma-
cro lipase and the non-Hodgkin lymphoma of the
patient. In support of this we observed a close rela-
tionship between the clinical state of disease, success
of therapy, relative amount of -globulins, and activ-
ity of macro lipase. During unsuccessful therapy and
tumour growth, macro lipase activity increased (fig.
1); during successful therapy, the activity of macro
lipase decreased to values below the upper reference
limit for serum lipase activity. In the latter case, chro-
matography showed a very small macro lipase peak,
and the lipase binding capacity of the serum was very
low. We further conclude that it is unlikely that af-
fections of the pancreas are responsible for the pres-
ence of macro lipase in our patient's serum, but that
the amount of macro lipase observed is the result of
the concentration and the affinity of the circulating
antibodies and the amount of lipase released from the
pancreas. A physiological and/or pathobiochemical
function of this type of antibody prodtiction against
endogenous proteins like lipase
 ; still obscure and
hardly understood.
In routine and emergency laboratories, the determi-
nation of activities of serum lipase and amylase are
well established in the evaluation of patients present-
ing with possible pancratitis. Ön the one hand, the
existence of isoenzymes and macro amylase decreases
the specificity of amylase and may lead to diagnostic
confusion, so that hyperamyläsaeniia älone cäniiot be
used to diagnose pancreatitis. On the other band,
significantly increased serum lipase values are re-
garded to be very specific indicators for acute pan-
creatitis or affections of organs close to the pancreas
(2), in spite of the evidence of multiple fqrms of serum
lipase (l, 34—36). The interesting pattern, however,
first observed in pur patient, showed that serum lipase
activity may well be significantly elevated in some
cases where amylase activity remains normal and
there is no clinical evidence of abdominal distress or
acute inflammation of the pancreas. Differential di^
agnosis of abdominal diseases may be complicated by
the presence of macro lipase, which, like macro am-
ylase, may be responsible for falsely elevated serum
activities in a minority of cases.
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